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Background and objectives: Breast cancer is one of the most common causes of cancer-related deaths in women
worldwide. Studies on glucosylceramide synthase (GCS) activity suggest that this enzyme has a role in the
development of multidrug resistance in many cancer cells. However, few studies have shown the expression of GCS
in invasive ductal breast cancer and breast intraductal proliferative lesions.
Methods: In total, 196 samples from patients with invasive ductal breast cancer and 61 samples of breast intraductal
proliferative lesions were collected. Immunohistochemical analyses were conducted to determine the expression of
GCS and other related proteins.
Results: Expression of GCS was high in estrogen receptor (ER)-positive and HER-2 negative samples. In contrast,
the expression of GCS in invasive ductal cancer was significantly lower than that in intraductal proliferative lesions.
Conclusion: Our data demonstrates a correlation between the expression of the GCS protein and ER-positive/HER-2
negative breast cancer. Furthermore, in contrast to previous reports, the expression of GCS protein was shown to be
much higher in ductal carcinoma in-situ than that in invasive ductal cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1559854430111589.
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Breast cancer is one of the most common causes of can-
cer deaths in women worldwide [1]. The prognosis of
breast cancer has been improved significantly by com-
prehensive therapy including surgical methods, chemo-
therapy, endocrine therapies and molecular targeted
therapy. However, multidrug resistance (MDR) has been
a major barrier to improved survival rates among breast
cancer patients. MDR refers to the resistance of tumors
not only to individual cytotoxic drugs used in chemo-
therapy, but also to cross-resistance to a range of drugs
with different structures and cellular targets [2].* Correspondence: sunyuping@live.cn
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stated.P-glycoprotein (P-gp, P170), encoded by the MDR1
gene (ABCB1) in humans is the major cause of
multidrug resistance in breast cancer. P-gp is a member
of the adenosine triphosphate-binding cassette (ABC)
superfamily of membrane transporters, which bind and
hydrolyze ATP. The energy produced in this reaction is
used to drive the active transport of various molecules
across the plasma membrane or the intracellular mem-
branes of organelles, such as the endoplasmic reticulum,
peroxisomes, and mitochondria. A wide range of anti-
cancer agents are actively extruded by P-gp, leading to
chemoresistance [3].
Many studies have indicated that MDR1 is regulated
by glucosylceramide synthase (GCS), which is a pivotal
enzyme in the regulation of cellular ceramide [4]. Stud-
ies on GCS activity suggest that the enzyme plays a roleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient and tumor characteristics for the 143
reference invasive ductal breast cancer data series
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http://www.diagnosticpathology.org/content/9/1/22in the development of MDR in many cancer cells [5,6].
A number of methods that suppress the expression of
GCS, such as specific inhibitors, antisense oligonucleo-
tides and siRNA, have been shown to render MDR cells
chemosensitive [7,8]. Gouaze et al. suggested that GCS
blockade resensitizes MDR breast cancer cells to anti-
cancer drugs by downregulation of P-glycoprotein [9].
Liu et al. further demonstrated that GCS upregulates
MDR1 expression to regulate cancer drug resistance
through cSrc and beta-catenin signaling [10].
Few studies have shown the expression of GCS in
breast cancer tissue samples. In 2009, Ruckhäberle et al.
analyzed microarray data that showed GCS mRNA ex-
pression levels in 1,681 breast tumors [11], but few data
have demonstrated the expression of the GCS protein in
breast cancer. In 2011, Liu et al. detected GCS expres-
sion levels in normal tissues and certain cancer tissues;
however, this investigation was conducted in only a
small number of samples [12]. Zhang et al. showed the
relationship between chemotherapy and GCS expression
in invasive breast cancer tissue. However, there are cur-
rently no reports describing the expression of GCS in
clinical samples of intraductal proliferative breast le-








ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal
growth factor-2.Methods
Clinical samples
Tissue samples from 257 patients who underwent
complete dissection of the breast and axillary lymph
nodes (breast cancer patients) or local lumpectomy (pa-
tients with intraductal proliferative lesions or patients with
accessory breast) were collected at the Qilu Hospital and
Provincial Hospital, Shandong University, China, between
January 2006 and June 2010. No patients had preoperative
chemotherapy and informed consent for pathological
evaluation was obtained from all patients prior to surgery.
Paraffin-embedded tumor samples were prepared from
196 patients with invasive ductal breast carcinoma,
25 patients with ductal carcinoma in-situ (DCIS), 11
patients with atypical ductal hyperplasia (ADH), 25 pa-
tients with usual ductal hyperplasia (UDH) and five pa-
tients with accessory breast. Histopathologic variables,
including tumor size, lymph node metastasis, histologic
subtype, and histologic grade, were determined by
reviewing pathology reports and hematoxylin and eosin
stained (H&E) sections. Patient and tumor characteris-
tics are summarized in Tables 1 and 2. Forty of the
ductal breast carcinoma patients received clinical follow-
up at a median of 63 months (range, 15–68 months).
The use of these tissues was approved by the Research
Ethics Committee of Shandong Medical University and
we obtained written informed consent from all partici-
pants involved in our study.Cell culture
The multidrug-resistant breast cancer cell line, MCF-7/
ADM, was selected from the drug sensitive breast cancer
cell line MCF-7 using Doxorubicin in stages. Cells were
maintained in RPMI 1640 medium supplemented with
10% (v/v) fetal bovine serum (FBS) in a humidified at-
mosphere containing 5% CO2 at 37°C. Cells were then
seeded on glass slides for 24 h. Overexpression of GCS
protein by MCF-7/ADM cells was confirmed for use of
these cells as a positive control in this study [13].Morphologic parameters
Two pathologists, an experienced senior pathologist and
a less experienced junior pathologist reevaluated all of
the tumor slides stained with hematoxylin and eosin
(HE) for the following morphological features and the
histological tumor type according to WHO 2003 classification.
Table 2 Patients and tumor characteristics for the 25
reference breast cancer in-situ data set (n = 25)
























ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal
growth factor-2.
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[14]:
1. Grading factors: Histological grade was assessed
using the modified Bloom-Richardson method, in
which tubule formation/grade of the tumor, nuclear
pleomorphism/atypia (nuclear grade), mitotic count
were scored. Mitotic count was performed on
Olympus BX51 light microscope, with a graticule
at × 40 magnification and in 10 high-power fields
(HPFs). Mitotic number was scored as 1 when it
was between 0–7, 2 when between 8–14 and 3 when
15 or more.
2. Architectural features of the tumor:
i. Tumor growth pattern was assessed as infiltrative
if there was irregular infiltration into the
surrounding parenchyma or fat or pushing if the
tumor was well circumscribed.
ii. Necrosis with its type was noted as present or
absent. Large confluent areas of tumor necrosis
with an irregular outline called as
geographicnecrosis and the necrosis in the middleof the tumor islands was called as central
necrosis.
iii. Stromal lymphocytic response was scored as
none, mild (less than 25% of the tumor),
moderate (25 to 50% of the tumor) and marked
(>50% of the tumor).
iv. Presence or absence of carcinoma in situ was
determined.
v. Presence of central scar, defined as the central
fibrotic, sclerotic, predomi
3. Cytological features of the tumor cells:
i. Presence of nucleoli were scored as absent or
prominent if they were easily visible at low power
ii. Amount of the tumor cell cytoplasm was assessed
as scant, moderate or copious according to
nuclear-cytoplasm ratio.
iii. Presence of vesicular chromatin pattern was
noted.
Immunocytochemical and immunohistochemical analyses
Immunohistochemical staining was carried out using the
DAKO Envision detection kit (Dako, Carpinteria, CA,
USA). In brief, paraffin-embedded tissue blocks were
sectioned (4 μm-thick), dried, deparaffinized, and rehy-
drated. Antigen retrieval was performed in a microwave
oven for 15 min in 10 mM citrate buffer (pH 6.0). After
cells were embedded in 4% neutral formaldehyde for
2 h, PBS with 0.5% Tween-20 was added for 30 min at
room temperature. For all samples, endogenous peroxid-
ase activity was blocked with a 3% H2O2-methanol solu-
tion. The slides were blocked with 10% normal goat
serum for 10 min and incubated with an appropriately
diluted primary antibody overnight at 4°C. The slides
were then probed with an HRP-labeled polymer conju-
gated to an appropriate secondary antibody for 30 min.
The antibodies against estrogen receptor (ER), progester-
one receptor (PR), HER-2, Ki67, cytokeratin 5/6 (CK5/6)
and epidermal growth factor receptor (EGFR) were pur-
chased from Dako (Carpinteria, CA, USA) and the GCS
antibody was a gift from Dr. D. Marks (Mayo Clinic
Center).
Interpretation
Staining results were interpreted by a breast pathologist
who was blinded to patient outcomes. Tumors with 1%
or more positively stained nuclei were considered posi-
tive for ER and PR expression [15]. Ki67 staining was de-
termined to be positive when more than 14% of the
nuclei were stained. Membranous staining for EGFR and
cytoplasmic staining for CK5/6 and HER-2 were scored
by counting the number of positively stained cells on the
membrane and expressed as a percentage of total tumor
cells according to the American Society of Clinical
Oncology (ASCO) and the College of American Pathologists
Figure 1 Immunohistochemical analyses of GCS protein in different sample types. GCS protein expression detected in all samples by
immunohistochemical and cytoplasmic staining was considered positive. Images are representative of two cases that were predominantly
positive in DCIS (A) or IDC (B), respectively. DCIS-ductal carcinoma in situ; IDC-invasive ductal carcinoma.
Table 3 The correlation between GCS and the







Age <35 3 5 0.035*
≥35 101 34
Tumor stage T1-2 50 22 0.453
T3-4 54 17
Nodal stage N0 27 15 0.375
N1-x 23 14
Histologic grade Grade I 15 1 0.045
Grade II-Ш 89 38
ER Positive 73 31 0.017
Negative 19 20
PR Positive 69 22 0.271
Negative 35 17
HER-2 Positive 22 17 0.007*
Negative 82 22
Ki67 <14% 23 7 0.652
≥14% 81 32
*P < 0.05.
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal
growth factor-2.
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http://www.diagnosticpathology.org/content/9/1/22(CAP) guidelines using the following categories: 0, no
immunostaining; 1+, weak, incomplete membranous
staining in any proportion of tumor cells; 2+, complete
membranous staining, either non-uniform or weak in at
least 10% of tumor cells; and 3+, uniform, intense
membranous staining in >30% of tumor cells. HER-2
results were considered positive in cases with 3 + mem-
branous staining of IHC or gene amplification by fluor-
escence in-situ hybridization (FISH) irrespective of IHC
results using the diagnostic criteria described [16].
A dual semi-quantitative scale combining staining in-
tensity and percentage of positive cells was used to
evaluate GCS protein staining. The staining intensity
was scored as 0 (negative), 1 (weak), 2 (moderate), or 3
(strong). The percentage of positive cells was scored as
follows: 0, no staining or staining in <5% of tumor cells;
1, staining in 5% to 25% of cells; 2, staining in 26% to
50% of cells; 3, staining in 51% to 75% of cells; and 4,
staining in >75% of cells. For GCS, cytoplasmic staining
was considered positive, with an IHC score ≥2 defined
as high expression and <2, as low expression [13].
Fluorescence in-situ hybridization
In cases of HER-2 IHC staining of 2+, fluorescence in-
situ hybridization (FISH) analysis was performed manu-
ally using the PathVysion HER-2 DNA Probe Kit (Abott,
Abott Park, IL, USA) according to the manufacturer’s in-
structions. In brief, consecutive sections from formalin-
fixed, paraffin-embedded tissue blocks were mounted on
Probe On Plus microscope slides (Fisher Scientific,
Pittsburgh, PA, USA), deparaffinized in xylene, and sub-
sequently rehydrated in ethanol. Sections were then
boiled for 10 min in pretreatment solution, incubated
with pepsin solution for 10 min, dehydrated in ethanol
for 6 min, and finally air-dried. For hybridization, the
buffered probe (HER-2/neu and centromere 17) was
added to the slide and protected by a coverslip that was
sealed with rubber cement. For denaturation, slides wereheated to 82°C and incubated overnight at 45°C in a dark,
humidified chamber. The rubber cement and coverslip were
then removed, and the slides were transferred to stringent
wash buffer for 10 min at 65°C. Sections were then dehy-
drated in ethanol for 6 min and air-dried before being
counterstained with 40, 6-diamidino-2- phenylindole
(DAPI). Evaluation of signals was carried out using an epi-
fluorescence microscope (Leica, Germany). Counting was
carried out according to the manufacturer’s instructions
(HER-2/neu gene, orange; centromere 17, green). As rec-
ommended by the ASCO/CAP guidelines, an absolute
Figure 2 Patient survival curves. Kaplan-Meier survival curves for patients with invasive ductal breast carcinoma were calculated according to
GCS protein expression status. No correlation was observed between GCS overexpression and A) recurrence-free survival or B) overall survival.
Figure 3 Correlation between GCS expression and breast tumor
molecular subtypes.
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http://www.diagnosticpathology.org/content/9/1/22HER-2 gene copy number greater than 6 or HER-2 gene/
chromosome 17 copy number ratio higher than 2.2 was
considered HER-2 positive. Lymphocytes, fibroblasts, and
normal ductal epithelial cells were used as internal controls.
Definition of breast tumor subtypes
Breast tumor subtypes were defined as follows: luminal
A (ER + and/or PR+, HER-2-), luminal B (ER + and/or
PR+, HER-2+), HER-2 positive (ER-, PR-, HER-2+), and
basal-like (ER-, PR-, HER-2-, Ck5/6 or EGFR+) [14].
Statistical analysis
Chi-square or Fisher’s exact tests was used to analyze
the relationship between the expression of GCS and
each histopathological variable. Survival curves were
plotted using the Kaplan-Meier method and were com-
pared using the log-rank test. P-values less than 0.05
were considered statistically significant. All calculations
were performed using the SPSS16.0 for windows statis-
tical software package (SPSS, Chicago, IL, USA).
Results
Expression of GCS protein in breast tissue samples
The expression of GCS protein was detected in all sam-
ples by immunohistochemical staining. Figure 1 show
positively and negative staining in invasive ductal breast
cancer of breast samples (Figure 1 and Table 3).
Correlation between GCS expression and
clinicopathological parameters
Overall, 72.7% of all the invasive carcinoma samples
were positive for GCS (104/143), while only 93.4% of the
intraductal proliferative lesions were positive (57/61).
The expression level of the GCS protein in the intraductalproliferative lesions was significantly higher than that in
the invasive ductal carcinoma (P < 0.05).
In the invasive cancers, there was a significant correl-
ation between the GCS upregulation and ER positivity
(P = 0.017) or HER-2 negativity (P = 0.007). We also
found that positive rates of GCS expression were higher
in grade I (93.75%, 15/16) than those in the grade II–III
(70.08%, 89/127) (P = 0.045) (Table 3). A higher positive
rate of GCS expression was observed in younger patients
(aged <35 years) compared with that in older patients
(aged ≥35 years).
There was no statistical significance in the relationship
between GCS expression and other clinicopathological
parameters, including age, tumor size, nodal stage, Ki67
(Table 3).Correlation between the GCS expression and the survival
There was no statistical significance in the relationship
between GCS expression and overall survival (Figure 2).
Liu et al. Diagnostic Pathology 2014, 9:22 Page 6 of 7
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molecular subtypes
The positive rate of GCS was highest in luminar A tumors
and was lowest in basal-like tumors. However, there was
no statistically significant difference in the GCS expression
levels between the four breast tumor subtypes (Figure 3).
Discussion
Breast cancer is one of the most frequent and deadly
cancers in women, with an estimated 1,300,000 new
cases and 465,000 deaths annually [17]. Multidrug resist-
ance is one of the main impediments to the successful
treatment of breast cancer. The mechanisms underlying
MDR are complex and overexpression of P-gp is consid-
ered to be an important factor.
Recent research has indicated that the expression of
P-gp is related to the activity of GCS, an enzyme that
glycosylates ceramide and inhibits its proapoptotic activity
in cells. Zhang et al. revealed that the expression of the
GCS gene in the drug-resistant human breast cancer cell
line MCF-7/ADM is higher than that in drug sensitive
cells, and that the sensitivity of MCF-7/ADM cells to
adriamycin is enhanced by GCS inhibition [18]. Further-
more, GCS expression has been found to confer MDR in
many other cancers [19,20]. MDR1 and GCS have been
shown to be overexpressed coincidently in several drug-
resistant cell lines, a phenomenon that indicates a rela-
tionship between these two proteins. In 2010, Liu et al.
demonstrated for the first time that GCS upregulates
MDR1 expression resulting in the modulation of drug resist-
ance in the ovarian drug-resistant cell line NCI/ADR-RES
through the cSrc and beta-catenin signaling pathway [10].
In 2009, microarray analysis of 1,681 breast tumors
conducted by Ruckhäberle et al. revealed that GCS
mRNA expression was associated with positive ER sta-
tus, lower histological grading, low Ki67 levels and
ErbB2 negativity (P < 0.001 for all) [8]. In 2011, Liu et al.
detected GCS expression levels in normal tissues and
certain cancer tissues. Their results showed that GCS
overexpression is highly associated with ER-positive and
HER-2-positive breast cancers that have metastasized
[12]; however, this was a small study. Our results
demonstrated that GCS protein expression was higher in
ER-positive samples (P < 0.05) (Table 3), which was in
accordance with both of these previous studies.
Human epidermal growth factor receptor 2 (HER2)
protein, encoded by the oncogene HER2, is amplified in
20–30% of breast cancer cases and is the target of
HER2-directed anti-cancer therapies [21]. Our research
shows that there was a significant correlation between
GCS expression and low HER-2 status in the invasive
ductal cancer samples (Table 3), which was in accordance
with the study of Ruckhäberle et al., although our observa-
tion that GCS protein levels did not correlate with Ki67.Our study demonstrated a higher positive rate of GCS
expression in breast cancer samples from younger pa-
tients (aged <35 years) expressed lower levels of GCS
protein than older patients (aged ≥35 years) (60% vs.
74.8%, P = 0.035). Otherwise, we found that the expres-
sion of GCS was higher in the cancer T1-2 than that in
the cancer T3-4.
Breast cancer is accounting for 23% (1.38 million) of the
total new cancer cases and 14% (458,400) of the total can-
cer deaths in 2008 worldwide. Metastasis and recurrence
severely affect the quality and length of lives of breast can-
cer patients [22]. Although the study of Liu demonstrated
that GCS overexpression is highly associated with ER-
positive and HER-2-positive breast cancers that have
metastasized [12], our study demonstrated that GCS ex-
pression has no correlation with lymph metastasis.
Our data also showed that, in contrast to previous re-
ports, GCS protein expression was much higher in DCIS
than that in the invasive ductal cancer.
Conclusions
In conclusion, our data demonstrate that GCS protein
expression is correlated with ER-positive and HER-2
negative breast cancers. Furthermore, intraductal prolif-
erative breast lesions were shown to express significantly
higher levels of GCS than that detected in invasive
ductal breast cancers.
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